Furugaki and colleagues validated that erlotinib inhibited osteolytic bone invasion which was induced by human NSCLC cell line NCI-H292 (EGFR wild type cell line) in SCID mice [21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.